User profiles for Kittiyod Poovorawan
 | Kittiyod PoovorawanFaculty of Tropical Medicine, Mahidol Universiity Verified email at mahidol.ac.th Cited by 1121 |
[HTML][HTML] Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication
…, S Akkarathamrongsin, K Poovorawan… - World journal of …, 2014 - ncbi.nlm.nih.gov
Hepatitis C virus (HCV) is a serious public health problem affecting 170 million carriers
worldwide. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and is the primary …
worldwide. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and is the primary …
[HTML][HTML] Hepatitis E virus infection: Epidemiology and treatment implications
GY Lee, K Poovorawan, D Intharasongkroh… - World journal of …, 2015 - ncbi.nlm.nih.gov
Hepatitis E virus (HEV) infection is now established as an emerging enteric viral hepatitis.
Standard treatments in acute and chronic hepatitis E remain to be established. This study …
Standard treatments in acute and chronic hepatitis E remain to be established. This study …
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
…, Y Tanaka, SH Jeong, K Poovorawan… - The Lancet …, 2024 - thelancet.com
The top 20 highest burdened countries (in disability-adjusted life years) account for more
than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is …
than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is …
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised …
…, B Hanboonkunupakarn, K Poovorawan… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …
antiviral treatments, but their antiviral activities in patients have not been compared …
The incidence, etiologies, outcomes, and predictors of mortality of acute liver failure in Thailand: a population-base study
…, N Soonthornworasiri, K Poovorawan… - BMC …, 2019 - Springer
Background Acute liver failure (ALF) is uncommon but progresses rapidly with high mortality.
We investigated the incidence, etiologies, outcomes, and predictive factors for 30-day …
We investigated the incidence, etiologies, outcomes, and predictive factors for 30-day …
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
…, B Hanboonkunupakarn, K Poovorawan… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
…, B Hanboonkunupakarn, S Sookprome, K Poovorawan… - ELife, 2023 - elifesciences.org
Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
…, S Sookprome, K Poovorawan… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
Characteristics and associated factors of acute kidney injury among adult dengue patients: a retrospective single-center study
…, W Phumratanaprapin, B Phonrat, K Poovorawan… - PLoS …, 2019 - journals.plos.org
Severe dengue cases have been increasingly reported in Thailand, and the under-reporting
of acute kidney injury (AKI) in cases of dengue viral infection has become an obstacle in …
of acute kidney injury (AKI) in cases of dengue viral infection has become an obstacle in …
[HTML][HTML] Towards the elimination of viral hepatitis in Thailand by the year 2030
Viral hepatitis is a global problem with mortality comparable to HIV, tuberculosis and malaria.
The WHO aims to eliminate hepatitis B (HBV) and hepatitis C (HCV) by 2030. Improved …
The WHO aims to eliminate hepatitis B (HBV) and hepatitis C (HCV) by 2030. Improved …
